Image named ‘Oncology Innovation of the Year’ at the 2022 BioTech Breakthrough Awards

Annual awards program recognizes innovation in the global life sciences and biotechnology industry

TEL AVIV, Israel – November 3, 2022 – (

Imagean emerging leader in the field of AI-based precision oncology, announced today that it has been selected as “Oncology Innovation of the Year” at the second annual BioTech Breakthrough Awards program conducted by biotechnological breakthrougha leading independent market intelligence organization that evaluates and recognizes outstanding life sciences and biotechnology companies, products and services worldwide.

The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the leading companies, solutions and products in the life sciences and biotechnology industry today. This year’s show attracted more than 1,350 nominations from more than 12 different countries around the world. Imagene’s AI-based biomarker detection was chosen as a groundbreaking innovation in the field of medical technology.

Imagene is a pioneering startup in the digital genomics space. Using computer vision algorithms, the company can detect cancerous genomic alterations in real time directly from the scanned image of the biopsy (H&E) slide. The idea behind Imagene’s innovative development aligns with the notion that actionable (controlling) genomic alterations will have a morphological effect on tissue at a resolution that is impossible for the human eye to detect, but AI and learning models deep they can.

“We are honored to be recognized among these great innovators in life sciences and biotechnology as we continue to advance precision oncology in the fight against cancer,” said Dean Bitan, Co-Founder and CEO of Imagene. “The cancer diagnostic process has evolved to include crucial genomic information; however, the long response time, fabric, and cost make their availability limited. The identification of genetic alterations is key to improving patient care and guiding specific therapeutic decisions; Physicians must be able to make optimal treatment decisions in a timely and accurate manner. The availability of rapid molecular analysis can sometimes be the difference between life and death.”

“According to NCCN guidelines, the identification of patient-specific actionable genomic alterations serves as the foundation of precision oncology and is routinely used to make optimal, personalized treatment decisions that drive higher response rates and mortality. The need to use biological samples and the long time required for analysis and interpretation, as well as inadequate tissue biopsies, mean that patients are not receiving life-saving treatment quickly enough,” said Bryan Vaughn, CEO BioTech Breakthrough Awards. “Imagene’s innovative solution paves the way for fast and accurate cancer diagnosis, demonstrating the breakthrough that AI-based genomic testing can bring to the care of cancer patients. Our deepest congratulations on winning ‘Oncology Innovation of the Year!’”

Imagene has developed 28 different models for actionable alterations in eight types of cancer, including lung, colorectal, bladder, breast, ovarian, hematology, thyroid, and brain cancer. The detection accuracy level aligns with current gold standard methodologies showing an average sensitivity that is higher than standard of care. Imagene’s real-time image-based biomarker detection takes about two minutes, significantly reduces cost and time with high scalability and seamless integration with routine workflows.

About the image

Imagene is a precision oncology diagnostics company with a mission to help cancer patients receive the optimal treatment that medicine can offer by leveraging AI to detect, in real time, a wide range of cancer biomarkers and clinical information using only digitized biopsy images. Its multidisciplinary team is comprised of a diverse group of experts from the fields of science, medicine, and deep learning. Imagene collaborates with top-tier medical centers and pharmaceutical companies around the world, striving for rapid and accurate cancer diagnosis, profiling patients for clinical trials, and accelerating the drug development process. For more information visit

About the biotech breakthrough

Part of Technological advance, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is dedicated to honoring excellence in biotechnology and life sciences solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including biopharmaceuticals, genomics, therapeutics, food science, and bioagriculture, among others. For more information visit

Contact information:

Avital Rabbani

Marketing Manager

[email protected]

Press Release Service

original source:

Image named ‘Oncology Innovation of the Year’ at the 2022 BioTech Breakthrough Awards

Leave a Comment